P-glycoprotein function in the elderly

被引:46
作者
Brenner, SS [1 ]
Klotz, U [1 ]
机构
[1] Dr Margarete Fischer Bosch Inst Clin Pharmacol, D-70376 Stuttgart, Germany
关键词
P-glycoprotein; elderly; rhodamine efflux;
D O I
10.1007/s00228-004-0733-4
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Objective. The MDR1-encoded P-glycoprotein (Pgp) represents the best-studied membraneous efflux pump defending the body against xenobiotics. Various polymorphisms (single nucleotide polymorphisms; SNPs) in the MDR1 gene have been identified, and a silent mutation in exon 26 (C3435T) has been correlated with duodenal expression of Pgp, which might affect the disposition of certain drugs. The C3435T SNP has been shown to be linked to another SNP (G2677T/A) in exon 21 which leads to an amino acid exchange. So far, the influence of age on Pgp function has been neglected. As the function of Pgp might be altered in advanced age, we investigated in groups of fit and frail elderly subjects whether the efflux of the Pgp-probe rhodamine 123 from CD56(+) natural killer cells was age dependent and whether it was affected by the two SNPs. Methods. Leukocytes were isolated from blood of 18 healthy elderly subjects (mean age 69 years) and 20 geriatric frail patients (mean age 78 years) and data compared with 21 previously studied young healthy Caucasian individuals (mean age 33 years). Subjects were homozygous for either CC- or TT-genotype (SNP C3435T) and additionally differentiated according to genotype GG or TT of the SNP G2677T. Using flow cytometry, rhodamine fluorescence was monitored in CD56(+) cells. Results. In contrast to the young controls, in both elderly populations no significant difference between the CC and TT genotypes (exon 26) could be observed in rhodamine fluorescence. Furthermore, only for the TT genotype (exon 26) did frail elderly demonstrate some reduced Pgp function (P=0.03) if compared with the young healthy subjects. If the three groups were compared independent of the genotype, no age effects were observed. For all assessed genotypes, there was no significant difference between fit and frail elderly subjects. Conclusion. Aging and frailty have apparently only a minor impact on this validated cellular Pgp model and it could be assumed that function of Pgp is quite well preserved in patients of advanced age.
引用
收藏
页码:97 / 102
页数:6
相关论文
共 44 条
  • [1] MDR1 pharmacogenetics:: frequency of the C3435T mutation in exon 26 is significantly influenced by ethnicity
    Ameyaw, MM
    Regateiro, F
    Li, T
    Liu, XH
    Tariq, M
    Mobarek, A
    Thornton, N
    Folayan, GO
    Githang'a, J
    Indalo, A
    Ofori-Adjei, D
    Price-Evans, DA
    McLeod, HL
    [J]. PHARMACOGENETICS, 2001, 11 (03): : 217 - 221
  • [2] Mammalian ABC transporters in health and disease
    Borst, P
    Elferink, RO
    [J]. ANNUAL REVIEW OF BIOCHEMISTRY, 2002, 71 : 537 - 592
  • [3] Pharmacogenetics of the human drug-transporter gene MDR1:: impact of polymorphisms on pharmacotherapy
    Brinkmann, U
    Roots, I
    Eichelbaum, M
    [J]. DRUG DISCOVERY TODAY, 2001, 6 (16) : 835 - 839
  • [4] Calado RT, 2002, HAEMATOLOGICA, V87, P564
  • [5] CAMPBELL MJ, 1995, BRIT MED J, V311, P145
  • [6] Frequency of single nucleotide polymorphisms in the P-glycoprotein drug transporter MDR1 gene in white subjects
    Cascorbi, I
    Gerloff, T
    Johne, A
    Meisel, C
    Hoffmeyer, S
    Schwab, M
    Schaeffeler, E
    Eichelbaum, M
    Brinkmann, U
    Roots, I
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 2001, 69 (03) : 169 - 174
  • [7] Cvetkovic M, 1999, DRUG METAB DISPOS, V27, P866
  • [8] MDR1 gene polymorphisms and disposition of the P-glycoprotein substrate fexofenadine
    Drescher, S
    Schaeffeler, E
    Hitzl, M
    Hofmann, U
    Schwab, M
    Brinkmann, U
    Eichelbaum, M
    Fromm, MF
    [J]. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2002, 53 (05) : 526 - 534
  • [9] Adenosine triphosphate-binding cassette transporter genes in ageing and age-related diseases
    Efferth, T
    [J]. AGEING RESEARCH REVIEWS, 2003, 2 (01) : 11 - 24
  • [10] Drug therapy - Pharmacogenomics - Drug disposition, drug targets, and side effects
    Evans, WE
    McLeod, HL
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2003, 348 (06) : 538 - 549